ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, single center, non-randomized study to evaluate the
absorption, distribution, metabolism and excretion (ADME) of an oral solution of radiolabeled
Ibrexafungerp following repeat administration in healthy male subjects. All subjects will
undergo preliminary screening procedures, will remain the clinical unit for approximately 26
days and will receive radiolabeled Ibrexafungerp, orally for 3 days.